Active pharmaceutical ingredient (API) materials and excipients possess physical and chemical characteristics that extend well beyond molecular identity. Crystal form, particle size, morphology, thermal behavior, moisture interactions, impurities, and solid-state transformations all influence manufacturing performance and finished-product quality. Triclinic Labs combines complementary analytical techniques to build a complete understanding of pharmaceutical materials, enabling clients to reduce development risk, strengthen regulatory submissions, and make better manufacturing decisions.
Bulk powder characterization measures physical, surface, and particulate attributes such as bulk/tapped density, flow, particle size, microscopy, water uptake, contact angle, surface energy, and milling or agglomeration behavior.
Use it when powders behave differently despite passing chemical specifications, when milling/clogging/flow/segregation occur, or when dry-powder functionality, excipient choice, and formulation robustness need evidence.
Powder tests are highly dependent on sample history, humidity, handling, consolidation, particle shape, and scale. A single powder number rarely predicts performance without process context.
Sample amount depends on technique, matrix, replicate needs, detection limit, current good manufacturing practice (cGMP) requirements, and whether method development or validation is required. Confirm exact amounts at project intake.
Particle-size analysis, microscopy, scanning electron microscopy with energy-dispersive X-ray spectroscopy (SEM/EDX), dynamic vapor sorption (DVS) for humidity-response behavior, Karl Fischer (KF) titration for water content, contact-angle analysis, powder-flow testing, X-ray powder diffraction (XRPD), Raman spectroscopy, and thermal analysis compete or complement one another depending on whether the issue involves particle size, morphology, solid form, moisture, surface properties, or flow.
FDA-facing work should connect the method to a quality attribute, document sample preparation and specificity, and support validation or verification where the result is used for release, stability, or regulatory decisions.
Common mistakes include reporting instrument results without explaining what they mean for the material or project decision.
Triclinic uses bulk-powder characterization to solve practical API, excipient, and formulated-material questions involving lot comparability, powder flow, blending, milling, compaction, dissolution risk, and stability. Real-world work often combines particle size, morphology, crystallinity, water content, surface behavior, and solid-form evidence so a powder problem can be tied to a material attribute rather than treated as a generic processing issue.
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Malvern Mastersizer 3000 | Malvern Mastersizer 3000 v.3.70; Malvern Access Configurator v.2.20 | Laser diffraction particle-size analysis; dry range 0.1-3500 um and wet range 0.01-1400 um; supports cGMP and non-GMP method development, verification, transfer, validation, and release testing. |
| Hall FlowMeter AS-300 | Hall FlowMeter AS-300 | Powder flow rate and apparent-density testing for free-flowing metallic, ceramic, pharmaceutical, and other fine powders. |
| Contact-angle / wetting platform | Rame-Hart imaging system with Drop Image Advanced Software v.1.4.11 and automated dispensing system | Powder and surface wettability, contact-angle, advancing/receding wetting, and surface-energy support. |
| True-density pycnometry | Micromeritics 1305 Multi-Volume Pycnometer | True-density measurement for powders, porous materials, irregular solids, catalysts, pigments, ceramics, and pharmaceutical materials. |
| Optical and digital microscopy | Leica M80 stereo microscope; Leica DM2500P compound/polarizing microscope; Keyence VHX-2000E digital microscope; Pax-it2! v.1.4.3 software | Still/dynamic image capture, polarized-light microscopy, particle habit, topography, and morphology documentation. |
| SEM/EDX platform | Thermo Phenom XL SEM/EDX with integrated backscattered electron detector; Oxford INCA PentFETx3 energy-dispersive X-ray spectroscopy system | Particle morphology, localized elemental analysis, elemental mapping, and contaminant or heterogeneity investigations. |
| Karl Fischer water determination | Mettler Toledo V20 and C20 systems, including oven KF support | Volumetric and coulometric water-content analysis for solids, liquids, formulations, and samples requiring oven-assisted water release. |
| Moisture interaction support | TA Instruments Q5000 DVS systems with Thermal Advantage for Q Series v.5.4.0 | Moisture uptake/release, water-vapor sorption isotherms, hygroscopicity, and humidity-driven powder behavior. |
This example focuses on a common powder-development problem: an active pharmaceutical ingredient can pass required physicochemical specifications and still behave differently in the mill, during blending, or during downstream handling. An API batch before and after milling met specifications but clogged the mill. The case illustrates why bulk-powder characterization must look beyond a single specification result and connect morphology, particle size, agglomeration, flow, water uptake, and surface behavior to process performance.
These examples include technical resources, regulatory guidances, or literature relevant to the technique. Download buttons are placed at the bottom-left of each example.
Author: Melanie Bevill, Chris Seadeek, Nico Setiawan, Shawn Comella, Blaise Mibeck, and Steef Boerrigter
Publication date: November 2023
Abstract: Solid-form screening and selection connect crystallinity, stability, solubility, hygroscopicity, manufacturability, regulatory needs, and IP objectives. Analytical techniques should therefore be selected according to the development decision rather than a fixed instrument list.
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: FDA notes that ICH Q2(R2) and Q14 describe validation and development principles for analytical procedures used to assess drug substance and drug product quality. These guidances frame FDA expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence.
Author: International Council for Harmonisation
Publication date: 2022
Abstract: ICH Q3D(R2) provides the risk-management framework for assessing and controlling elemental impurities in drug products. It is the regulatory anchor for elemental-impurity testing, method selection, and justification of inductively coupled plasma mass spectrometry (ICP-MS), X-ray fluorescence (XRF), or other elemental-analysis strategies.
Use this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueBulk powder characterization measures physical, surface, and particulate attributes such as bulk and tapped density, powder flow, particle size, microscopy, water uptake, contact angle, surface energy, and milling or agglomeration behavior.
Use it when powders behave differently despite passing chemical specifications, when milling, clogging, flow, segregation, or agglomeration problems occur, or when dry-powder functionality, excipient choice, and formulation robustness need evidence.
Chemical specifications may not capture particle shape, agglomeration, surface energy, moisture interaction, consolidation history, or flow behavior. These physical attributes can drive manufacturing performance even when identity, assay, or impurity results are acceptable.
Sample amount depends on the technique, matrix, replicate needs, detection limit, cGMP requirements, and whether method development or validation is required. Exact amounts should be confirmed at project intake.
Particle-size analysis, microscopy, SEM/EDX, DVS for humidity-response behavior, Karl Fischer titration for water content, contact-angle analysis, powder-flow testing, XRPD, Raman spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and thermal analysis can be combined depending on whether the problem appears to involve particle size, morphology, solid form, moisture, surface properties, chemistry, or flow.
FDA-facing work should connect the measurement to a quality attribute, document sample handling and specificity, and support validation or verification where the result is used for release, stability, comparability, or other regulatory decisions.
Common mistakes include reporting instrument results without explaining what they mean for the material or project decision, using non-representative material, ignoring humidity and handling history, failing to document sample preparation, or not using orthogonal methods when one test is not specific enough.
Often, yes. Differences in particle size, shape, surface area, density, moisture response, cohesion, flow, electrostatics, or agglomeration can help explain blending, feeding, compression, coating, filtration, or transfer problems.
We'd be happy to discuss bulk powder characterization approaches to measure physical, surface, particulate attributes such as bulk/tapped density, flow, particle size, microscopy, water uptake, contact angle, surface energy, and milling or agglomeration behavior. Click the button to get started...
